BioNTech Gets $445 Million in German Funding for Vaccine
- Partner Pfizer has said human data may be available next month
- CureVac and IDT Biologika also in line for government funds
This article is for subscribers only.
BioNTech SE will get as much as 375 million euros ($445 million) from Germany to back its Covid-19 vaccine program, about half of the money the government set aside to accelerate development of immunizations.
The German biotech company is working with Pfizer Inc. and Shanghai Fosun Pharmaceutical Group Co. on what is expected to be one of the first vaccines to deliver results from late-stage human trials. Pfizer has repeatedly said data from a U.S. study could be ready next month.